Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BNTX
- Price
- 106.53
- Stock movement up
- +2.13 (2.04%)
- Company name
- BioNTech SE
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 25.54B
- Ent værdi
- 19.20B
- Pris/omsætning
- 8.40
- Pris/bog
- 1.34
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- 20.45%
- 3 års afkast
- -7.55%
- 5 års afkast
- 15.94%
- 10 års afkast
- -
Senest opdateret: 2025-06-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UDBYTTE
BNTX betaler ikke udbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | 16.78 |
| Pris til FCF | 26.33 |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 8.40 |
| Pris til egenkapital | 1.34 |
| EV i forhold til salg | 6.32 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 239.74M |
| EPS (TTM) | -1.91 |
| FCF pr. aktie (TTM) | 3.97 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 3.04B |
| Bruttofortjeneste (TTM) | 2.56B |
| Driftsindkomst (TTM) | -936.70M |
| Nettoindkomst (TTM) | -466.90M |
| EPS (TTM) | -1.91 |
| EPS (1 år frem) | -3.34 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 84.31% |
| Driftsmargin (TTM) | -30.81% |
| Fortjenstmargin (TTM) | -15.36% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 9.62B |
| Nettotilgodehavender | 1.20B |
| Omsætningsaktiver i alt | 18.49B |
| Goodwill | 374.00M |
| Immaterielle aktiver | 873.90M |
| Ejendomme, anlæg og udstyr | 1.16B |
| Sum aktiver | 22.40B |
| Kreditor | 762.60M |
| Kortfristet/nuværende langsigtet gæld | 243.70M |
| Summen af kortfristede forpligtelser | 2.52B |
| Sum gæld | 3.29B |
| Aktionærernes egenkapital | 19.11B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 1.52B |
| Investeringsudgifter (TTM) | 551.93M |
| Fri pengestrøm (TTM) | 969.97M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -2.44% |
| Afkast af aktiver | -2.08% |
| Afkast af investeret kapital | -2.41% |
| Kontant afkast af investeret kapital | 5.01% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 104.45 |
| Daglig høj | 107.51 |
| Daglig lav | 104.41 |
| Daglig volumen | 723K |
| Højeste gennem alle tider | 447.23 |
| 1 års analytiker estimat | 137.65 |
| Beta | 0.26 |
| EPS (TTM) | -1.91 |
| Udbytte pr. aktie | - |
| Ex-div dato | 2 Jun 2022 |
| Næste dato for resultatpræsentation | - |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BNTX | S&P500 | |
| Nuværende prisfald fra top notering | -76.18% | -3.04% |
| Højeste prisfald | -82.48% | -56.47% |
| Højeste efterår dato | 5 Aug 2024 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -53.00% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 25 days | 12 days |
| Maks. tid til nyt højdepunkt | 971 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
25.54B
Markedsværdi kategori
Large-cap
Beskrivelse
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Personale
6133
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Ugur Sahin
Land
USA
By
Mainz
Aktietype
American depositary share
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Seeking AlphaPressemeddelelser
iO Charts is a Seeking Alpha partnerNæste side